Dendl, Katharina
Koerber, Stefan A.
Adeberg, Sebastian
Röhrich, Manuel
Kratochwil, Clemens
Haberkorn, Uwe
Giesel, Frederik L.
Funding for this research was provided by:
Projekt DEAL
Article History
Received: 26 November 2020
Accepted: 13 January 2021
First Online: 4 February 2021
Compliance with ethical standards
:
: The radiopharmaceutical was used on an individual patient basis according to German Pharmaceuticals Act §13(2b). The patient gave written informed consent to receive the novel diagnostics and permitted anonymized publication of related medical data. The ethical committee of Heidelberg University approved this retrospective evaluation to be in accordance with the Helsinki declaration. For case reports from clinical practice, no trial registration is required.
: UH, CK, and FLG have a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine. UH, CK, and FLG have shares of iTheranostics.FLG is a medical advisor for ABX Advanced Biochemical Compound and Telix Pharmaceuticals. SA received grants from Accuray International Sàrl, Merck Serono GmbH, Novocure GmbH, MSD, and Astra Zeneca outside the submitted work. S.A. Novocure GmbH, Actinium Pharmaceuticals, Telix Pharmaceuticals shareholding.SAK reports grants from Viewray Inc., outside the submitted work.